CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it granted equity inducement awards to four newly hired non-executive employees, a move that highlights the company’s effort to attract talent as it expands around its newly approved liver disease therapy.
The awards, granted December 15, 2025, totaled 1,394 time-based restricted stock units and were approved by Madrigal’s independent Compensation Committee under the company’s 2025 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and were material to the employees’ acceptance of employment.
The restricted stock units vest in four equal annual installments over four years, with vesting contingent on continued employment at each anniversary date. Madrigal said the awards are intended to align employee incentives with long-term shareholder value as the company advances its commercial and clinical priorities.
Madrigal is focused on treatments for metabolic dysfunction-associated steatohepatitis, or MASH, a serious liver disease with significant unmet medical need. Its drug Rezdiffra, also known as resmetirom, is the first and only therapy approved by both U.S. and European regulators for patients with moderate to advanced fibrosis. The company is also running a Phase 3 outcomes trial evaluating the drug in patients with compensated MASH cirrhosis.
Equity inducement awards are commonly used by growth-stage biopharmaceutical companies to compete for specialized talent without expanding executive compensation. For Madrigal, the grants signal continued investment in its workforce as it shifts from development toward broader commercialization and late-stage clinical execution.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.